Phase II Randomized Study of Docetaxel With or Without Low-dose, Short Course Sunitinib in the Treatment of Advanced Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2018
At a glance
- Drugs Docetaxel (Primary) ; Sunitinib (Primary)
- Indications Breast cancer; Gastric cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Therapeutic Use
- 21 Jun 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2018.
- 07 Jun 2016 Interim results (n=46) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 01 May 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.